AU732703B2 - An improved method for the production and purification of adenoviral vectors - Google Patents

An improved method for the production and purification of adenoviral vectors Download PDF

Info

Publication number
AU732703B2
AU732703B2 AU53617/98A AU5361798A AU732703B2 AU 732703 B2 AU732703 B2 AU 732703B2 AU 53617/98 A AU53617/98 A AU 53617/98A AU 5361798 A AU5361798 A AU 5361798A AU 732703 B2 AU732703 B2 AU 732703B2
Authority
AU
Australia
Prior art keywords
cells
adenovirus
antisense
virus
chromatography
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU53617/98A
Other languages
English (en)
Other versions
AU5361798A (en
Inventor
Toohyon Cho
Capucine Thwin
Zhang Wu
Shuyuan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Introgen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21858843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU732703(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Introgen Therapeutics Inc filed Critical Introgen Therapeutics Inc
Publication of AU5361798A publication Critical patent/AU5361798A/en
Application granted granted Critical
Publication of AU732703B2 publication Critical patent/AU732703B2/en
Assigned to CRUCELL HOLLAND B.V. reassignment CRUCELL HOLLAND B.V. Alteration of Name(s) in Register under S187 Assignors: INTROGEN THERAPEUTICS, INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cleaning And De-Greasing Of Metallic Materials By Chemical Methods (AREA)
  • Multi-Process Working Machines And Systems (AREA)
  • Saccharide Compounds (AREA)
AU53617/98A 1996-11-20 1997-11-20 An improved method for the production and purification of adenoviral vectors Expired AU732703B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3132996P 1996-11-20 1996-11-20
US60/031329 1996-11-20
PCT/US1997/021504 WO1998022588A2 (en) 1996-11-20 1997-11-20 An improved method for the production and purification of adenoviral vectors

Publications (2)

Publication Number Publication Date
AU5361798A AU5361798A (en) 1998-06-10
AU732703B2 true AU732703B2 (en) 2001-04-26

Family

ID=21858843

Family Applications (1)

Application Number Title Priority Date Filing Date
AU53617/98A Expired AU732703B2 (en) 1996-11-20 1997-11-20 An improved method for the production and purification of adenoviral vectors

Country Status (14)

Country Link
US (7) US6194191B1 (enExample)
EP (3) EP0968284B1 (enExample)
JP (1) JP4492826B2 (enExample)
KR (1) KR100503701B1 (enExample)
CN (1) CN1244215B (enExample)
AT (2) ATE348155T1 (enExample)
AU (1) AU732703B2 (enExample)
BR (1) BR9713368A (enExample)
CA (1) CA2272820C (enExample)
DE (1) DE69737107T2 (enExample)
ES (2) ES2383640T3 (enExample)
NO (1) NO992389L (enExample)
NZ (1) NZ335947A (enExample)
WO (1) WO1998022588A2 (enExample)

Families Citing this family (288)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2230655C (en) * 1995-08-30 2008-06-17 Genzyme Corporation Chromatographic purification of adenovirus and aav
US20020088014A1 (en) * 1996-05-31 2002-07-04 Xiangming Fang Minimal adenovirus mediated recombinant vaccine
US6485958B2 (en) 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6544769B1 (en) 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6989264B2 (en) * 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2307016A1 (en) * 1997-10-24 1999-05-06 Life Technologies, Inc. Recombinational cloning using nucleic acids having recombination sites
US7705602B2 (en) * 1997-11-03 2010-04-27 Midtronics, Inc. Automotive vehicle electrical system diagnostic device
US20040204381A1 (en) * 1997-11-12 2004-10-14 Moskal Joseph R Detection and treatment of glyco-enzyme-related disease
US6899870B1 (en) * 1998-03-11 2005-05-31 Board Of Regents, The University Of Texas System Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
EA200001096A1 (ru) * 1998-04-22 2001-04-23 Джинвек, Инк. Способ обогащения раствора аденовируса, способ точного подсчета числа аденовирусных частиц в образце раствора (варианты) и способ очистки аденовируса из клеток, инфицированных аденовирусом
US6416992B1 (en) * 1998-10-13 2002-07-09 Avigen, Inc. Compositions and methods for producing recombinant adeno-associated virus
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1133316B1 (en) * 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7148035B1 (en) * 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
US6210922B1 (en) * 1998-11-30 2001-04-03 National Research Council Of Canada Serum free production of recombinant proteins and adenoviral vectors
NZ512504A (en) 1998-12-31 2004-01-30 Aventis Pharma Sa Method for separating viral particles
FR2788064B1 (fr) * 1998-12-31 2003-01-31 Aventis Pharma Sa Methode de separation de particules virales
WO2000050573A1 (fr) 1999-02-22 2000-08-31 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US6795585B1 (en) 1999-07-16 2004-09-21 Eastman Kodak Company Representing digital images in a plurality of image processing states
AU2911501A (en) * 1999-12-29 2001-07-09 Genzyme Corporation Method using filtration aids for the separation of virus vectors from nucleic acids and other cellular contaminants
US6168941B1 (en) * 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
JP2004509065A (ja) * 2000-04-28 2004-03-25 ゼンジェン　インコーポレイテッド α−ＭＳＨおよびその誘導体を用いる遺伝子治療システムおよび方法
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20020064860A1 (en) * 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
EP1370643A1 (en) * 2001-03-16 2003-12-17 Oncolytics Biotech, Inc. Method of extracting virus from cell culture
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
MXPA03008882A (es) * 2001-03-27 2003-12-08 Vertex Pharma Composiciones y metodos utiles para la infeccion por hcv.
WO2003014367A1 (en) 2001-08-08 2003-02-20 The Trustees Of The University Of Pennsylvania Method for purification of viral vectors having proteins which bind sialic acid
WO2003020893A2 (en) * 2001-08-30 2003-03-13 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services New adenovirus type 7 vectors
WO2003023026A1 (en) * 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
AU2002348151A1 (en) * 2001-11-05 2003-05-19 Genvec, Inc. Viral vector production methods and compositions
EA006485B1 (ru) * 2001-12-20 2005-12-29 Бавариан Нордик А/С Способ выделения и очистки поксвирусов из инфицированных клеток
KR100451308B1 (ko) * 2001-12-28 2004-10-06 선바이오(주) 단백질 의약품 정제 방법에서의 바이러스 제거 방법
WO2003068993A1 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Method for isolation and purification of expressed gene products in vitro
JP2005517942A (ja) * 2002-02-20 2005-06-16 メルク　エンド　カムパニー　インコーポレーテッド アデノ粒子濃度の測定方法
US20030186832A1 (en) * 2002-03-15 2003-10-02 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Isotropic liquid detergents with improved anti-redeposition
US20030180936A1 (en) * 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
US20030175688A1 (en) * 2002-03-15 2003-09-18 Rukmini Pennathur-Das Method for the purification and production of oncolytic adenoviruses
CA2478932A1 (en) * 2002-03-29 2003-10-16 Merck & Co., Inc. Large scale methods of producing adenovirus and adenovirus seed stocks
DK1501921T4 (da) * 2002-04-30 2012-10-08 Oncolytics Biotech Inc Forbedrede virusrensningsmetoder
EP1783212B1 (en) * 2002-05-14 2011-01-05 Merck Sharp & Dohme Corp. Methods of adenovirus purification
US20030224354A1 (en) * 2002-05-30 2003-12-04 Introgen Therapeutics Inc. Quantifying viral particles with intrinsic fluorescence
EP1371723A1 (en) * 2002-06-12 2003-12-17 Procorde GmbH Process for preparing an adenovirus-containing preparation
JP2005532829A (ja) * 2002-07-18 2005-11-04 インヴィトロジェン コーポレーション 組換え部位を含むウイルスベクター
AU2003268210A1 (en) * 2002-08-28 2004-03-19 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
WO2004030635A2 (en) * 2002-10-03 2004-04-15 Targegen, Inc. Vasculostatic agents and methods of use thereof
EP1558748A4 (en) * 2002-11-01 2008-10-22 Promega Corp CELL SYSE COMPOSITIONS, USE METHOD, DEVICE AND KIT
EP1585812B1 (en) 2002-12-13 2017-01-18 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
BRPI0317276B8 (pt) * 2002-12-13 2021-05-25 Alphavax Inc método para a preparação de partículas de replicon de alfavírus (arps)
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
EP1594433B8 (en) 2003-01-14 2016-12-21 Dana-Farber Cancer Institute, Inc. Cancer therapy sensitizer
WO2004085660A2 (en) * 2003-03-20 2004-10-07 Alphavax, Inc. Improved alphavirus replicons and helper constructs
ATE371014T1 (de) * 2003-05-01 2007-09-15 Dsm Ip Assets Bv Verfahren zur herstellung von biologischen substanzen durch perfusionskultivierung von suspendierten tierischen zellen
US20040229335A1 (en) * 2003-05-15 2004-11-18 Introgen Therapeutics, Inc. Methods and compositions for the production of adenoviral vectors
AU2004249199B2 (en) * 2003-06-18 2008-07-24 Onyx Pharmaceuticals, Inc. Method for purifying virus
AU2004257214B2 (en) * 2003-07-11 2010-04-22 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
US8304189B2 (en) * 2003-12-01 2012-11-06 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
EP1697505A1 (en) * 2003-12-23 2006-09-06 Schering Corporation Methods for producing a549 cell lines stable in serum-free medium suspension culture
CA2555412C (en) 2004-02-23 2013-06-25 Crucell Holland B.V. Virus purification methods
CN100333797C (zh) * 2005-01-26 2007-08-29 彭朝晖 重组腺病毒p53制品在肿瘤治疗中的新用途
EP1809614B1 (en) 2004-04-08 2014-05-07 TargeGen, Inc. Benzotriazine inhibitors of kinases
US20050266550A1 (en) 2004-05-18 2005-12-01 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
EP1751275B1 (en) * 2004-06-01 2017-08-16 Avigen, Inc. Compositions and methods to prevent aav vector aggregation
US20050287616A1 (en) * 2004-06-29 2005-12-29 Gross Adam F Method of assaying denaturation of proteins
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
DE202004014949U1 (de) * 2004-09-25 2004-11-18 Techno-Grafica Gmbh Vorrichtung zum Wärmebehandeln einer Beschichtung von Flachoffset-Druckplatten
DE102004049290A1 (de) * 2004-10-09 2006-04-20 Bayer Healthcare Ag Verfahren zur Herstellung von Virusmaterial
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
WO2006052302A2 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying adenoviral vectors
CN100497640C (zh) * 2004-11-26 2009-06-10 中国人民解放军军事医学科学院生物工程研究所 一种高效生产重组腺病毒载体的方法
US20060166364A1 (en) * 2004-12-22 2006-07-27 Introgen, Inc. Use of flexible bag containers for viral production
CN103555670B (zh) 2004-12-23 2015-08-12 米迪缪尼有限公司 用于病毒增殖的非致瘤性mdck细胞系
US20060205080A1 (en) * 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
MX2007011064A (es) 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
ATE412737T1 (de) * 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
MX2007013725A (es) * 2005-05-05 2008-04-09 Sensient Flavors Inc Produccion de beta-glucanos y mananos.
US20060292203A1 (en) * 2005-06-08 2006-12-28 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
US20090216452A1 (en) * 2005-07-05 2009-08-27 Develop Tech Resources Energy recovery within a fluid distribution network using geographic information
MX391408B (es) * 2005-11-01 2025-03-21 Impact Biomedicines Inc Inhibidores de biaril meta-pirimidina de cinasas.
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
EP2322931A3 (en) * 2006-03-22 2011-08-31 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
WO2007127366A2 (en) * 2006-04-25 2007-11-08 Targegen, Inc. Kinase inhibitors and methods of use thereof
CA2663522C (en) * 2006-09-15 2015-06-02 Medimmune, Llc Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
PE20081723A1 (es) 2007-01-30 2008-12-14 Transgene Sa Vacuna contra el papilomavirus
US20080299624A1 (en) * 2007-06-01 2008-12-04 Edward Heslop Continuous fermentation apparatus and method
DK2183368T3 (en) * 2007-06-21 2016-09-05 Alphavax Inc PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS
ES2636460T3 (es) * 2007-10-08 2017-10-05 Intrexon Corporation Células dendríticas modificadas por ingeniería y usos para el tratamiento del cáncer
EP2612868B1 (en) 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
US20090253184A1 (en) * 2008-01-23 2009-10-08 Introgen Therapeutics, Inc. Compositions and methods related to an adenoviral trans-complementing cell line
JP5733796B2 (ja) * 2008-05-13 2015-06-10 ジェン−プロウブ インコーポレイテッド 標的核酸配列の選択的ハイブリダイゼーションおよび捕捉における使用のため不活化可能型標的捕捉オリゴマー
EP2307551B1 (en) * 2008-06-18 2016-12-14 Oxford BioMedica (UK) Limited Purification of retroviral vectors
KR20110074564A (ko) * 2008-09-24 2011-06-30 메디뮨 엘엘씨 세포 배양, 바이러스 증식 및 바이러스 정제를 위한 방법
WO2010036774A1 (en) 2008-09-24 2010-04-01 Medimmune, Llc Methods for purification of viruses
ES2532015T3 (es) 2008-11-03 2015-03-23 Crucell Holland B.V. Método para la producción de vectores adenovíricos
AU2009319979B2 (en) * 2008-11-03 2016-10-20 Takeda Vaccines, Inc. Improved methods for isolating enveloped virus-based VLPs free of infectious agents
WO2010136979A2 (en) * 2009-05-26 2010-12-02 Leviathan Energy Hydroelectric Ltd. Hydroelectric in-pipe turbine uses
CN103331186A (zh) * 2009-07-07 2013-10-02 索尼公司 微流体装置
NZ598000A (en) 2009-08-07 2013-10-25 Transgene Sa Composition for treating hbv infection
WO2011045378A1 (en) 2009-10-15 2011-04-21 Crucell Holland B.V. Method for the purification of adenovirus particles
MX2012004221A (es) 2009-10-15 2012-06-08 Crucell Holland Bv Proceso para purificacion de adenovirus de cultivos de alta densidad celular.
NZ601325A (en) 2010-01-05 2014-09-26 Vascular Biogenics Ltd Compositions and methods for treating glioblastoma gbm
JP6196040B2 (ja) 2010-01-05 2017-09-13 バスキュラー バイオジェニックス リミテッド 特異的な抗血管形成アデノウイルス剤の使用法
EP2523681A1 (en) * 2010-01-12 2012-11-21 Vascular Biogenics Ltd. Methods of producing adenovirus vectors and viral preparations generated thereby
ES2578514T3 (es) 2010-02-15 2016-07-27 Crucell Holland B.V. Método para la producción de vectores adenovíricos
WO2011130119A2 (en) * 2010-04-14 2011-10-20 Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
US8778653B2 (en) 2010-08-12 2014-07-15 Yisheng Biopharma Holdings Ltd. Method for reducing DNA impurities in viral compositions
CN103118702A (zh) 2010-09-20 2013-05-22 克鲁塞尔荷兰公司 活动性结核病的治疗性接种
AU2011310838B2 (en) 2010-09-27 2015-11-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
EP2461162A1 (en) 2010-12-03 2012-06-06 Texcell, . Method for determining the titre of viruses by using infectious standards
CA2819552C (en) 2010-12-09 2023-09-26 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
WO2015126403A1 (en) 2014-02-20 2015-08-27 Honeywell International Inc Lead-free solder compositions
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
ES2582504T3 (es) 2012-03-12 2016-09-13 Crucell Holland B.V. Lotes de adenovirus recombinantes con extremos alterados
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
MY169331A (en) 2012-03-22 2019-03-21 Janssen Vaccines & Prevention Bv Vaccine against rsv
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
WO2014016690A2 (en) * 2012-07-26 2014-01-30 Vectalys Method for detecting or measuring the impact of a viral vector composition on eukaryotic cells and biomarkers used thereof
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
TR201902513T4 (tr) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
WO2014179108A1 (en) 2013-05-03 2014-11-06 Honeywell International Inc. Lead frame construct for lead-free solder connections
KR102313153B1 (ko) 2013-06-17 2021-10-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
EP3063290B1 (en) * 2013-10-30 2018-11-21 Merck Patent GmbH Method for isolating microorganisms from a complex sample
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
DK3636742T3 (da) 2014-04-25 2025-11-24 Translate Bio Inc Fremgangsmåder til oprensning af messenger-rna
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
CN105316296A (zh) * 2014-06-13 2016-02-10 亚宝药业太原制药有限公司 一种纯化腺病毒颗粒的方法
US20180133252A9 (en) 2014-09-09 2018-05-17 Unum Therapeutics Inc. Chimeric receptors and uses thereof in immune therapy
GB201417042D0 (en) 2014-09-29 2014-11-12 Fkd Therapies Oy Method
SG10202007103TA (en) 2014-11-05 2020-09-29 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
KR20230169197A (ko) 2014-11-14 2023-12-15 보이저 테라퓨틱스, 인크. 근위축성 측삭 경화증(als)을 치료하는 조성물 및 방법
CN112375760A (zh) 2014-11-14 2021-02-19 沃雅戈治疗公司 调节性多核苷酸
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
US9862936B2 (en) 2015-01-13 2018-01-09 Alfa Wassermann, Inc. Methods of purifying adeno-associated virus (AAV) and/or recombinant adeno-associated virus (rAAV) and gradients and flow-through buffers therefore
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
CN107949397A (zh) 2015-02-13 2018-04-20 特兰斯吉恩股份有限公司 免疫治疗疫苗和抗体组合治疗
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017005844A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
US9663766B2 (en) 2015-07-24 2017-05-30 Bio-Rad Laboratories, Inc. Methods for purifying adenovirus vectors
CN116712535A (zh) 2015-10-16 2023-09-08 纽约市哥伦比亚大学理事会 用于抑制谱系特异性抗原的组合物和方法
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
KR102401247B1 (ko) 2016-04-05 2022-05-25 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
MY190320A (en) 2016-04-05 2022-04-13 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
KR102535013B1 (ko) * 2016-04-14 2023-05-22 트리젤 엘티디. 정유량 펌프/튜빙 시스템이 있는 고정층 바이오 리액터
KR102718795B1 (ko) 2016-04-14 2024-10-16 트리젤 엘티디. 정유량 펌프/튜빙 시스템이 있는 고정층 바이오 리액터
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
CN117904112A (zh) 2016-05-18 2024-04-19 沃雅戈治疗公司 调节性多核苷酸
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
CA3025441A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
CN109312362B (zh) 2016-06-20 2022-06-28 扬森疫苗与预防公司 有效和平衡的双向启动子
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
WO2018080573A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
US10294452B2 (en) 2016-11-22 2019-05-21 Dao-Yao He Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
CN108085301B (zh) * 2016-11-22 2021-10-26 贺道耀 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒
US20210405031A1 (en) * 2016-12-08 2021-12-30 Temple University - Of The Commonwealth System Of Higher Education Small animal models for in vivo testing of polyomavirus therapeutics
WO2018148246A1 (en) 2017-02-07 2018-08-16 Massachusetts Institute Of Technology Methods and compositions for rna-guided genetic circuits
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
CN119491003A (zh) 2017-05-05 2025-02-21 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
EP3808849A1 (en) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
CN107384873A (zh) * 2017-09-05 2017-11-24 成都汇宇生物技术有限公司 重组腺病毒的纯化方法
KR20200053518A (ko) 2017-09-15 2020-05-18 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 면역의 안전한 유도를 위한 방법
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
AU2018352236B2 (en) 2017-10-16 2025-04-10 The Curators Of The University Of Missouri Treatment of amyotrophic lateral sclerosis (ALS)
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN111527202B (zh) * 2017-11-08 2024-03-29 蓝天免疫疗法有限责任公司 So3色谱在病毒纯化方法中的应用
US20210010028A1 (en) 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
AU2019257755A1 (en) 2018-04-27 2020-11-12 Voyager Therapeutics, Inc. Methods for measuring the potency of AADC viral vectors
TW202015742A (zh) 2018-05-15 2020-05-01 美商航海家醫療公司 投遞腺相關病毒（ａａｖ）之組成物和方法
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
WO2019222444A2 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Directed evolution
WO2019222441A1 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
JP7565218B2 (ja) 2018-07-02 2024-10-10 ボイジャー セラピューティクス インコーポレイテッド 筋萎縮性側索硬化症および脊髄に関連する障害の治療
JP2021529559A (ja) 2018-07-03 2021-11-04 ソティオ，リミティド ライアビリティ カンパニー グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用
AU2019310459A1 (en) 2018-07-24 2021-02-18 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
IL280322B2 (en) 2018-08-14 2025-06-01 Sotio Llc Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof
US12172108B2 (en) 2018-08-16 2024-12-24 Emd Millipore Corporation Closed bioprocessing device
WO2020047164A1 (en) 2018-08-28 2020-03-05 Vor Biopharma, Inc Genetically engineered hematopoietic stem cells and uses thereof
KR102782761B1 (ko) 2018-09-21 2025-03-14 유니버시티 오브 코네티컷 인간의 앤젤만 증후군에서 부계 ube3a 유전자 발현을 복원하기 위한 조성물 및 방법
SG11202103151RA (en) 2018-09-28 2021-04-29 Voyager Therapeutics Inc Frataxin expression constructs having engineered promoters and methods of use thereof
AU2019354995B2 (en) 2018-10-02 2024-12-12 Voyager Therapeutics, Inc. Redirection of tropism of AAV capsids
TW202035689A (zh) 2018-10-04 2020-10-01 美商航海家醫療公司 測量病毒載體粒子的效價及強度之方法
US20210371470A1 (en) 2018-10-12 2021-12-02 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
JOP20210106A1 (ar) 2018-11-13 2023-01-30 Janssen Vaccines And Prevention B V بروتينات rsv f سابقة الاندماج مستقرة
CA3122085A1 (en) * 2018-12-11 2020-06-18 Erbi Biosystems, Inc. Methods of manufacturing cell based products using small volume perfusion processes
WO2020150556A1 (en) 2019-01-18 2020-07-23 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
JP2022521268A (ja) 2019-02-21 2022-04-06 アンリーシュ イミュノ オンカリティクス，インコーポレイテッド 腫瘍溶解性アデノウイルスベクター及び使用法
CN110093455B (zh) * 2019-04-27 2020-03-17 中国医学科学院病原生物学研究所 一种呼吸道病毒的检测方法
US20220243225A1 (en) 2019-04-29 2022-08-04 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
US20240124889A1 (en) 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
CN112175996A (zh) * 2019-07-05 2021-01-05 杭州荣泽生物科技有限公司 一种基因治疗载体的制备方法和用途
US20220290182A1 (en) 2019-08-09 2022-09-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
US20220364114A1 (en) 2019-08-26 2022-11-17 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2021046155A1 (en) 2019-09-03 2021-03-11 Voyager Therapeutics, Inc. Vectorized editing of nucleic acids to correct overt mutations
JP7761561B2 (ja) * 2019-11-15 2025-10-28 シティ・オブ・ホープ アデノ随伴ウイルスの増強された生産のための高密度細胞呼吸器を含むバイオプロダクトの生産のためのシステム、デバイスおよび方法
CN110894494B (zh) * 2019-11-22 2022-09-27 广西梧州制药（集团）股份有限公司 一种大规模高密度悬浮培养293细胞高产腺病毒的方法
US20230131352A1 (en) 2020-04-01 2023-04-27 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
KR20230020394A (ko) 2020-04-15 2023-02-10 보이저 테라퓨틱스, 인크. Tau 결합 화합물
GB202005732D0 (en) 2020-04-20 2020-06-03 Synpromics Ltd Regulatory nucleic acid sequences
CA3182970A1 (en) 2020-05-13 2021-11-18 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
EP4192514A1 (en) 2020-08-06 2023-06-14 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
CN112226418B (zh) * 2020-09-25 2022-07-08 阜外华中心血管病医院 重组腺相关病毒纯化方法
IL301955A (en) 2020-10-07 2023-06-01 Asklepios Biopharmaceutical Inc Therapeutic delivery of an adeno-related protein-related protein (FKRP) virus for the treatment of dystroglycanopathy disorders, including limb girdle 21
CN112293394B (zh) * 2020-10-30 2022-11-25 海南德安欣有害生物防治科技有限公司 一种捕鼠装置及捕鼠方法
US20230407328A1 (en) 2020-11-02 2023-12-21 Biomarin Pharmaceutical Inc. Process for enriching adeno-associated virus
GB202019454D0 (en) * 2020-12-10 2021-01-27 Chancellor Masters And Scholars Of The Univ Of Oxford Method for purifying virus
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240141377A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240189447A1 (en) 2021-04-16 2024-06-13 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
WO2023034996A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
US20240384242A1 (en) 2021-09-03 2024-11-21 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
US20240376495A1 (en) 2021-09-03 2024-11-14 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034990A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034989A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034980A1 (en) 2021-09-03 2023-03-09 Bomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
EP4405396A2 (en) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
MX2024004009A (es) 2021-09-27 2024-06-19 Sotio Biotech Inc Polipéptidos receptores quiméricos en combinación con moléculas transmetabólicas que redirigen metabolitos de glucosa fuera de la vía de la glucólisis y usos terapéuticos de estos.
KR20240113624A (ko) 2021-11-02 2024-07-22 보이저 테라퓨틱스, 인크. Aav 캡시드 변이체 및 이의 용도
AU2022388928A1 (en) 2021-11-16 2024-05-16 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
WO2023091948A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
EP4448099A1 (en) 2021-12-16 2024-10-23 University of Dundee Targeted degradation of alpha-synuclein
EP4469585A2 (en) 2022-01-25 2024-12-04 Voyager Therapeutics, Inc. Baculovirus expression system
IL314156A (en) 2022-02-08 2024-09-01 Voyager Therapeutics Inc Adeno-associated virus capsid variants and their uses
GB202201713D0 (en) 2022-02-10 2022-03-30 Univ Dundee An affinity directed phosphatase system for targeted protein dephosphorylation
CN115354033A (zh) * 2022-03-25 2022-11-18 上海碧博生物医药科技有限公司 一种细胞裂解液、细胞裂解方法及该方法在收获aav的应用
KR20250025387A (ko) 2022-06-02 2025-02-21 보이저 테라퓨틱스, 인크. Aav 캡시드 변이체 및 이의 용도
WO2024006741A1 (en) 2022-06-28 2024-01-04 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
TW202424201A (zh) 2022-07-06 2024-06-16 美商航海家醫療公司 Ａａｖ殼體變異體及其用途
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
WO2024040208A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
AU2023342086A1 (en) 2022-09-15 2025-03-13 Voyager Therapeutics, Inc. Tau binding compounds
WO2024064863A2 (en) 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
EP4590839A1 (en) 2022-09-22 2025-07-30 Dinaqor AG Treatment of cardiomyopathy with aav gene therapy vectors
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2024226790A1 (en) 2023-04-26 2024-10-31 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2024229163A1 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to cdkl5 deficiency
WO2024229164A2 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
AU2024265526A1 (en) 2023-05-03 2025-12-11 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
WO2024229173A2 (en) 2023-05-03 2024-11-07 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to ataxin-2
WO2024229425A1 (en) 2023-05-04 2024-11-07 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
WO2025038795A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
WO2025038430A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
WO2025038796A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to cdkl5 deficiency
AR133562A1 (es) 2023-08-16 2025-10-08 Voyager Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos relacionados con la deficiencia de frataxina
WO2025038805A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
WO2025038802A1 (en) 2023-08-16 2025-02-20 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to ataxin-2
WO2025122532A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to ataxin-2
WO2025122530A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
WO2025122543A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to syntaxin-binding protein 1 deficiency
WO2025122531A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to frataxin deficiency
WO2025122536A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
WO2025122548A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to cdkl5 deficiency
WO2025137219A1 (en) 2023-12-21 2025-06-26 Voyager Therapeutics, Inc. Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
WO2025147436A1 (en) 2024-01-03 2025-07-10 Voyager Therapeutics, Inc. Aav capsid variants and uses thereof
CN117551624A (zh) * 2024-01-11 2024-02-13 深圳源兴基因技术有限公司 一种基于无血清悬浮扩增的高效回收腺病毒的方法
WO2025214477A1 (en) 2024-04-12 2025-10-16 Skyline Therapeutics (Shanghai) Co., Ltd. Treatment of genetic cardiomyopathies with aav gene therapy vectors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996027677A2 (en) * 1995-03-07 1996-09-12 Canji, Inc. Method of purification of recombinant viral vectors containing a therapeutic gene

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US789244A (en) * 1902-10-01 1905-05-09 Hans Thormeyer Steam-turbine.
US824544A (en) * 1905-12-04 1906-06-26 George Hossege Pipe-hanger.
US4222743A (en) * 1978-07-20 1980-09-16 Wang Wei Kung Method and apparatus for detecting biological particles by fluorescent stain
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4539020A (en) * 1983-07-10 1985-09-03 Kawasaki Steel Corporation Methods for obtaining high-purity carbon monoxide
JPS6147187A (ja) 1984-08-10 1986-03-07 Chemo Sero Therapeut Res Inst 狂犬病ウイルスの精製方法
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5173418A (en) * 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5106841A (en) * 1986-05-13 1992-04-21 Chai-Tech Corporation Antiviral compositions and method for their use
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
JPH0761955B2 (ja) 1988-04-28 1995-07-05 国立予防衛生研究所長 凍結乾燥ａ型肝炎ワクチン
US5219752A (en) * 1988-05-25 1993-06-15 Teijin, Limited Process for continuously culturing adherent animal cells
EP0454777B1 (de) 1989-01-16 1994-06-08 Thomson Consumer Electronics Sales GmbH Kompatibles frequenzmultiplex-fernsehsystem
EP0470982B1 (de) * 1989-05-01 1993-07-14 BOHNENKAMP, Wolfram Reflexionsfluorimeter
DE69023488T2 (de) 1989-12-12 1996-05-09 Lidak Pharmaceuticals BESTIMMUNG FREIER FETTSäUREN.
IT1238231B (it) 1989-12-18 1993-07-12 Consiglio Nazionale Ricerche Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
NO312681B1 (no) 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
IT1248075B (it) 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
EP0552108B1 (en) * 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
US5323008A (en) * 1992-03-23 1994-06-21 Diatron Corporation Fluorometer detection system
PT713397E (pt) 1992-03-24 2003-04-30 United Cancer Res Inst Vacina que contem virus vivos
US5428011A (en) 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
US5733720A (en) * 1992-06-18 1998-03-31 Washington University Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor
WO1994002638A1 (en) * 1992-07-17 1994-02-03 Aprogenex, Inc. Free radical scavengers useful for reducing autofluorescence in fixed cells
CA2144848A1 (en) 1992-09-18 1994-03-31 H. Michael Shepard Gene therapy by retroviral vector with tumor suppressive gene
US5733721A (en) * 1992-11-20 1998-03-31 The Board Of Regents Of The University Of Oklahoma Cell analysis method using quantitative fluorescence image analysis
EP0682697A4 (en) 1993-01-29 1997-07-30 New Brunswick Scientific Co METHOD AND DEVICE FOR ANCHORING AND SUSPENSING CELL CULTURES.
US5604096A (en) * 1993-03-04 1997-02-18 Schaeffer; Warren I. Fluorometric quantitation of mycoplasmas
US5994314A (en) 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
WO1994026934A2 (en) 1993-05-06 1994-11-24 Baxter Diagnostics Inc. Human papillomavirus detection assay
US5421339A (en) * 1993-05-12 1995-06-06 Board Of Regents, The University Of Texas System Diagnosis of dysplasia using laser induced fluoroescence
US6686200B1 (en) * 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
AU7971194A (en) 1993-10-12 1995-05-04 Chiron Corporation Methods for preserving recombinant viruses
TW442569B (en) * 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
WO1995019427A1 (en) * 1994-01-12 1995-07-20 Genetic Therapy, Inc. Purification of retroviral vectors
HRP950097A2 (en) * 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
US5498537A (en) * 1994-03-09 1996-03-12 Cellco, Inc. Serum-free production of packaged viral vector
CA2186034C (en) 1994-03-22 2002-11-26 Michael E. Hrinda Highly efficient production and isolation of viral particles
US5521083A (en) * 1994-05-13 1996-05-28 The Research Foundation Of State University Of New York Et Al. Large granular lymphocyte leukemia associated virus
WO1996009399A2 (en) * 1994-09-23 1996-03-28 Somatix Therapy Corporation Chimeric adenovirus for gene delivery
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5744304A (en) * 1995-05-30 1998-04-28 Board Of Regents, The University Of Texas System Inflammation-induced expression of a recombinant gene
US5772888A (en) * 1995-07-27 1998-06-30 Massachusetts Institute Of Technology Separation and/or concentration of an analyte from a mixture using a two-phase aqueous micellar system
CN1122531C (zh) * 1995-08-01 2003-10-01 巴斯德梅诺血清和疫苗公司 抗日本脑炎疫苗的工业生产方法和所获得的疫苗
CA2230655C (en) 1995-08-30 2008-06-17 Genzyme Corporation Chromatographic purification of adenovirus and aav
CA2238829A1 (en) * 1995-11-30 1997-06-05 Board Of Regents, The University Of Texas System Methods and compositions for the diagnosis and treatment of cancer
US5910434A (en) * 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
AR006240A1 (es) * 1996-03-14 1999-08-11 Fuller H B Licensing Financ Adhesivo de fusion caliente que comprende interpolimeros, articulo no tejido que lo comprende, procedimiento de polimerizacion para preparlo y caja, envase, bandeja y libro unidos con dicho adhesivo
JPH09262099A (ja) * 1996-03-28 1997-10-07 Aisin Seiki Co Ltd フルオレセイン誘導体リン酸エステルによる核酸等の検出方法
US6485958B2 (en) 1996-07-01 2002-11-26 Gencell Sa Method for producing recombinant adenovirus
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
AU5370598A (en) 1996-12-13 1998-07-03 Schering Corporation Methods for purifying viruses
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6168944B1 (en) 1997-01-31 2001-01-02 Schering Corporation Methods for cultivating cells and propagating viruses
ES2287974T3 (es) 1997-02-18 2007-12-16 Canji, Inc. Terapia genica supresora de tumor y quimioterapia combinadas en el tratamiento neoplasmas.
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
US6130313A (en) 1997-10-02 2000-10-10 Clontech Laboratories, Inc. Rapidly degrading GFP-fusion proteins
JP4358434B2 (ja) 1998-02-17 2009-11-04 シェーリング コーポレイション ウイルスを含む組成物、およびウイルス調製物を濃縮するための方法
US5922576A (en) 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
CA2322202C (en) 1998-03-10 2010-11-30 Large Scale Proteomics Corporation Detection and characterization of microorganisms
US6265151B1 (en) * 1998-03-27 2001-07-24 Seroptix, Inc. Apparatus and method for infectious disease detection
EA200001096A1 (ru) * 1998-04-22 2001-04-23 Джинвек, Инк. Способ обогащения раствора аденовируса, способ точного подсчета числа аденовирусных частиц в образце раствора (варианты) и способ очистки аденовируса из клеток, инфицированных аденовирусом
US6171790B1 (en) * 1998-05-01 2001-01-09 Incyte Pharmaceuticals, Inc. Human protease associated proteins
WO1999060371A2 (en) 1998-05-15 1999-11-25 Geron Corporation Method and apparatus for detecting hazardous agents
AU740441B2 (en) * 1998-06-30 2001-11-01 La Mina Ltd Cytological and histological fixative composition and methods of use
WO2000008443A1 (en) 1998-08-08 2000-02-17 Imperial Cancer Research Technology Limited Multiple frequency fluorescence lifetime imaging
US5965358A (en) 1998-08-26 1999-10-12 Genvec, Inc. Method for assessing the relative purity of viral gene transfer vector stocks
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
NZ512504A (en) * 1998-12-31 2004-01-30 Aventis Pharma Sa Method for separating viral particles
US6316185B1 (en) * 1999-09-29 2001-11-13 Mountain View Pharmaceuticals, Inc. Quantitation of viruses by light scattering
JP2002054561A (ja) * 2000-08-08 2002-02-20 Toyota Industries Corp 容量可変型圧縮機の制御弁及び容量可変型圧縮機
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
DE10050114A1 (de) * 2000-10-09 2002-04-25 Wolf Gmbh Richard Verwendung einer Gelmasse
AU2003268210A1 (en) * 2002-08-28 2004-03-19 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
US20040229335A1 (en) * 2003-05-15 2004-11-18 Introgen Therapeutics, Inc. Methods and compositions for the production of adenoviral vectors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996027677A2 (en) * 1995-03-07 1996-09-12 Canji, Inc. Method of purification of recombinant viral vectors containing a therapeutic gene

Also Published As

Publication number Publication date
CA2272820C (en) 2012-09-11
KR100503701B1 (ko) 2005-07-26
US20030008375A1 (en) 2003-01-09
EP1760151B1 (en) 2012-03-21
ES2383640T3 (es) 2012-06-25
US20050089999A1 (en) 2005-04-28
NO992389D0 (no) 1999-05-19
ATE348155T1 (de) 2007-01-15
EP1707631A3 (en) 2006-12-27
DE69737107D1 (de) 2007-01-25
US7445930B2 (en) 2008-11-04
US20100055763A1 (en) 2010-03-04
NZ335947A (en) 2000-12-22
JP2001504701A (ja) 2001-04-10
US20070155008A1 (en) 2007-07-05
EP0968284A2 (en) 2000-01-05
ATE550429T1 (de) 2012-04-15
WO1998022588A2 (en) 1998-05-28
WO1998022588A3 (en) 1998-10-15
DE69737107T2 (de) 2007-07-12
US6194191B1 (en) 2001-02-27
JP4492826B2 (ja) 2010-06-30
CA2272820A1 (en) 1998-05-28
AU5361798A (en) 1998-06-10
HK1107116A1 (en) 2008-03-28
CN1244215A (zh) 2000-02-09
EP0968284B1 (en) 2006-12-13
US6726907B1 (en) 2004-04-27
EP1707631A2 (en) 2006-10-04
NO992389L (no) 1999-07-19
ES2278399T3 (es) 2007-08-01
CN1244215B (zh) 2010-11-03
US7510875B2 (en) 2009-03-31
KR20000057160A (ko) 2000-09-15
US20020177215A1 (en) 2002-11-28
BR9713368A (pt) 2001-09-18
EP1760151A1 (en) 2007-03-07

Similar Documents

Publication Publication Date Title
AU732703B2 (en) An improved method for the production and purification of adenoviral vectors
WO1998022588A9 (en) An improved method for the production and purification of adenoviral vectors
AU775579B2 (en) An improved method for the production and purification of adenoviral vectors
US20040106184A1 (en) Chromatographic methods for adenovirus purification
US20060166364A1 (en) Use of flexible bag containers for viral production
JP2007500015A (ja) アデノウイルスベクター産生のための方法および組成物
HK1099564A (en) An improved method for the production and purification of adenoviral vectors
WO1999027123A2 (en) Modified sv40 viral vectors
HK1107116B (en) Adenovirus compositions obtainable by an improved production and purification method

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)